BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11263504)

  • 1. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
    Sanson M; Napolitano M; Yaya R; Keime-Guibert F; Broët P; Hoang-Xuan K; Delattre JY
    J Neurooncol; 2000 Dec; 50(3):245-9. PubMed ID: 11263504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Forsyth P; Cairncross G; Stewart D; Goodyear M; Wainman N; Eisenhauer E
    Invest New Drugs; 1996; 14(2):203-6. PubMed ID: 8913841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of paclitaxel in patients with recurrent malignant glioma.
    Prados MD; Schold SC; Spence AM; Berger MS; McAllister LD; Mehta MP; Gilbert MR; Fulton D; Kuhn J; Lamborn K; Rector DJ; Chang SM
    J Clin Oncol; 1996 Aug; 14(8):2316-21. PubMed ID: 8708723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
    Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
    J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
    Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi N; Aoyama H; Taguchi T
    Br J Cancer; 1996 Jan; 73(2):210-6. PubMed ID: 8546908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
    Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
    Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study.
    Papakostas P; Kouroussis C; Androulakis N; Samelis G; Aravantinos G; Kalbakis K; Sarra E; Souglakos J; Kakolyris S; Georgoulias V
    Eur J Cancer; 2001 Oct; 37(15):1833-8. PubMed ID: 11576836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer.
    Mukohara T; Takeda K; Miyazaki M; Takifuji N; Terakawa K; Negoro S
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):356-60. PubMed ID: 11761452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
    Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
    Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
    Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
    Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
    J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD; Burris HA; Yardley DA; Bradof JE; Grimaldi M; Kalman LA; Sullivan T; Baker M; Erland JB; Greco FA
    J Clin Oncol; 2001 Aug; 19(15):3500-5. PubMed ID: 11481356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
    Lilenbaum RC; Schwartz MA; Seigel L; Belette F; Blaustein A; Wittlin FN; Davila E
    Cancer; 2001 Oct; 92(8):2158-63. PubMed ID: 11596033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
    J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.
    Postma TJ; Heimans JJ; Luykx SA; van Groeningen CJ; Beenen LF; Hoekstra OS; Taphoorn MJ; Zonnenberg BA; Klein M; Vermorken JB
    Ann Oncol; 2000 Apr; 11(4):409-13. PubMed ID: 10847458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
    Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
    J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
    Inuyama Y; Kataura A; Togawa K; Saijo S; Satake B; Takeoda S; Konno A; Ebihara S; Sasaki Y; Kida A; Kanzaki J; Ichikawa G; Kono N; Moriyama H; Kamata S; Miyake H; Sakai M; Horiuchi M; Kubota A; Tsukuda M; Matsuura H; Baba S; Saito H; Matsunaga T; Taguchi T
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):107-16. PubMed ID: 9987506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.